Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus LIPIODOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus LIPIODOL.
HYPAQUE-M,90% vs LIPIODOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Lipiodol is an iodinated ethyl ester of the fatty acids of poppyseed oil. It acts as a radiopaque contrast agent for imaging due to its iodine content, and in chemoembolization, it selectively accumulates in hepatocellular carcinoma (HCC) via tumor neovasculature and is retained due to lack of lymphatic drainage, allowing targeted delivery of chemotherapeutic agents.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Lymphangiography: 5-20 mL injected slowly into lymphatic vessels. Uterine/Fallopian tube imaging: 3-20 mL injected through cervix. Hepatic chemoembolization: 5-15 mL mixed with chemotherapeutic agents injected into hepatic artery.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal elimination half-life is approximately 50-60 days, reflecting slow clearance from lipid-rich tissues.
Renal: >95% unchanged; biliary/fecal: <5%
Primarily eliminated via biliary/fecal route as unchanged drug; less than 1% excreted renally.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent